63results about How to "Impede advancement" patented technology

The present invention provides methods of re-engineering or re-shaping an antibody from a first species, wherein the re-engineered or re-shaped antibody does not elicit undesired immune response in a second species, and the re-engineered or re-shaped antibody retains substantially the same antigen binding-ability of the antibody from the first species. In accordance with the present invention, a combinatorial library comprising the CDRs of the antibody from the first species fused in frame with framework regions derived from a second species can be constructed and screened for the desired modified antibody. In particular, the present invention provides methods utilizing low homology acceptor antibody frameworks for efficiently humanizing an antibody or a fragment thereof. The present invention also provides antibodies produced by the methods of the invention.

A lancing device and a removable and replaceable multi-lancet cartridge for use in connection therewith are disclosed. The multi-lancet cartridge is advanced through sequential lancets, and anti-reverse features prevent reverse advancement of the cartridge. Interlocks are provided to prevent double-cocking the device, to reduce the likelihood of jamming of the mechanism. Improved trigger mechanisms and depth control mechanisms are provided.

The present invention provides novel antibodies that immunospecifically bind to an IL-9 polypeptide and compositions comprising said antibodies. The present invention also provides methods and compositions preventing, treating, managing, and / or ameliorating diseases and disorders associated with aberrant expression and / or activity of IL 9 or IL-9 receptor or subunits thereof, autoimmune diseases, inflammatory diseases, proliferative diseases, and infections comprising administration of one or more antibodies thereof that immunospecifically bind to an IL-9 polypeptide. The invention also encompasses methods and compositions for diagnosing, monitoring, and prognosing these disorders. The present invention further relates to articles of manufacture and kits comprising antibodies that immunospecifically bind to an IL-9 polypeptide.

An open electrosurgical forceps includes a pair of first and second shaft members each having a jaw member disposed at its distal end. The jaw members are movable about a pivot assembly from an open position in spaced relation relative to one another to a closed position wherein the jaw members cooperate to grasp tissue. Each of the jaw members includes an electrically conductive sealing surface for communicating electrosurgical energy through grasped tissue. One or both of the jaw members includes a knife channel defined along its length. The pivot assembly includes a knife slot and is configured to prevent reciprocation of a cutting mechanism when the jaw members are disposed in the open position and to permit reciprocation of the cutting mechanism when the jaw members are disposed in the closed position. An actuator selectively advances the cutting mechanism from a first position to at least one subsequent position.

An open electrosurgical forceps includes a pair of first and second shaft members each having a jaw member disposed at its distal end. The jaw members are movable about a pivot assembly from an open position in spaced relation relative to one another to a closed position wherein the jaw members cooperate to grasp tissue. Each of the jaw members includes an electrically conductive sealing surface for communicating electrosurgical energy through grasped tissue. One or both of the jaw members includes a knife channel defined along its length. The pivot assembly includes a knife slot and is configured to prevent reciprocation of a cutting mechanism when the jaw members are disposed in the open position and to permit reciprocation of the cutting mechanism when the jaw members are disposed in the closed position. An actuator selectively advances the cutting mechanism from a first position to at least one subsequent position.

Syringes and methods of using are described which protect the syringe barrel cavity from contaminants. A first syringe is formed with a corrugated sheath or non-corrugated sheath which is positioned internal or external to the syringe barrel cavity. A second syringe is formed with a syringe barrel having a straight segment and a corrugated segment having the forward face of the plunger handle member molded to the rearward terminus of the corrugated segment of the syringe barrel. A third syringe is formed from mating syringe barrel and plunger member walls. The walls of the mating syringe barrel and plunger member are concentric and slide relative to each other while maintaining an enclosure around the plunger shaft. A fourth syringe is formed from inner and outer concentric syringe barrel walls mating with the walls of a plunger member. The mating walls are concentric and slide relative to each other while maintaining an enclosure around the plunger shaft. A fifth syringe is formed with an end cap contaminant shield having an extension wall that is mated with the inner wall surfaces of the syringe barrel cavity, or outer wall surfaces of the syringe barrel. Alternatively, the end cap contaminant shield can be provided with a flat design without the extending wall and is bonded or molded to the rearward end terminus of the syringe barrel. The end cap contaminant shield designs are provided with an opening defining the shape of the cross-section of the plunger shaft.

Renal infusion systems include an infusion catheter having a bifurcated distal end with a first branch and second branch, the branches being biased to deploy laterally when unconstrained. Systems also include a delivery sheath having a lumen which receives the infusion catheter and constrains the first branch and second branch. A distal opening of the delivery sheath is formed asymmetrically to allow one of the first and second branches to open laterally while the other of the branches remains constrained. Methods of using renal infusion systems are also provided.

The present invention provides novel antibodies that immunospecifically bind to an IL-9 polypeptide and compositions comprising said antibodies. The present invention also provides methods and compositions preventing, treating, managing, and / or ameliorating diseases and disorders associated with aberrant expression and / or activity of IL 9 or IL-9 receptor or subunits thereof, autoimmune diseases, inflammatory diseases, proliferative diseases, and infections comprising administration of one or more antibodies thereof that immunospecifically bind to an IL-9 polypeptide. The invention also encompasses methods and compositions for diagnosing, monitoring, and prognosing these disorders. The present invention further relates to articles of manufacture and kits comprising antibodies that immunospecifically bind to an IL-9 polypeptide.

A method is disclosed for receiving a plurality of play events associated with a sporting event, wherein each play event of the plurality of play events comprises a timestamp; for each of the play events, associating the play event with a sports team of a plurality of sports teams; for each of the play events, associating with the play event a particular icon from among a plurality of different icons based, at least in part, on the sports team that is associated with the play event; causing to display a bar in a graphical user interface of a mobile computing device, wherein the bar represents at least a portion of a time duration of the sporting event; for each of the play events, causing to display the particular icon at a position in the bar, wherein the position is based, at least in part, on the timestamp of the event.

A rock bolter has a drill and a bolt driver, both mounted to a turret that rotates relative to a base to align either the drill or the bolt driver with a work axis. A stinger / centralizer has two head elements, each advanced along a curvilinear path. When advanced, the head elements mate to provide a centralizer passage on the work axis. A supplementary stinger affixed to the base extends to engage the rock surface and provide stability as the head elements are retracted. The drill and the bolt driver are mounted on carriages activated by a common mechanism. A drill carriage disabling surface is affixed to the base to block the drill carriage when the drill is off the work axis, and a bolt driver carriage disabling surface is affixed to the base to block the bolt driver carriage when the bolt driver is off the work axis.

A method is disclosed for receiving a plurality of play events associated with a sporting event, wherein each play event of the plurality of play events comprises a game clock time, a description, and identifies a sports team of a plurality of sports teams; for each play event in the plurality of play events: generating a graphical tile that is associated with the play event; configuring an appearance of the graphical tile based, at least in part, on the description and the sports team of the play event; causing to display a graphical tile list in a graphical user interface of a mobile computing device, wherein the graphical tile list includes one or more of the graphical tiles listed in a chronological order based on the game clock time in the play event associated with each graphical tile.

The present invention relates to methods for identifying compounds that modulate untranslated region-dependent expression of a target gene. The invention particularly relates to using untranslated regions of a target gene or fragments thereof linked to a reporter gene to identify compounds that modulate untranslated region-dependent expression of a target gene. The methods of the present invention provide a simple, sensitive assay for high-throughput screening of libraries of compounds to identify pharmaceutical leads.

The present invention provides prophylactic an tehrapeutic protocols desinged to prevent, manage, treat, or ameliorate a respiratory condition or one or more symptoms thereof. In particular, the present invention provides methods for preventing, managinge, treating, or ameliorating a respiratory condition or one or symptoms caused by environmental factors or a respiratory infection. The present ivnention encompasses combination therapies, pharamceutical compositions, articles of manufacture, and kits.

The present invention provides novel antibodies that immunospecifically bind to an IL-9 polypeptide and compositions comprising said antibodies. The present invention also provides methods and compositions preventing, treating, managing, and / or ameliorating diseases and disorders associated with aberrant expression and / or activity of IL 9 or IL-9 receptor or subunits thereof, autoimmune diseases, inflammatory diseases, proliferative diseases, and infections comprising administration of one or more antibodies thereof that immunospecifically bind to an IL-9 polypeptide. The invention also encompasses methods and compositions for diagnosing, monitoring, and prognosing these disorders. The present invention further relates to articles of manufacture and kits comprising antibodies that immunospecifically bind to an IL-9 polypeptide.

A coaxial electrical connector comprises an outer conductor (10) having a tubular section (11); a central conductor (20) having a contact section (21) extending in the axial direction in the tubular section (11); and a dielectric block (30) molded to hold together both the conductors (10, 20). The central conductor (20) has a radial section (22) extending outwardly in the radial direction from the bottom of the contact section (21) and a connection portion (23A) on the bottom face of the radial section (22) for contact with a circuit board. The central conductor 20 has a surface-processed portion so as to form at least one of a raised portion (24) and an indented portion (22A) and is in contact with the dielectric block at the surface-processed portion.

A system and method are provided that use a balloon / stent catheter for placing a stent at the ostium of a blood vessel. Included is a barrier member that is attached to the catheter at a location proximal the balloon. In use, the barrier member is reconfigured, prior to insertion of the balloon / stent portion of the catheter through the ostium. With this reconfiguration, a barrier (array) is established that limits advancement of the catheter into the blood vessel to ensure proper placement of the stent at the ostium.

Renal infusion systems include an infusion catheter having a bifurcated distal end with a first branch and second branch, the branches being biased to deploy laterally when unconstrained. Systems also include a delivery sheath having a lumen which receives the infusion catheter and constrains the first branch and second branch. A distal opening of the delivery sheath is formed asymmetrically to allow one of the first and second branches to open laterally while the other of the branches remains constrained. Methods of using renal infusion systems are also provided.

The present invention encompasses the use of a CD2 antagonist, preferably MEDI-507, an analog, derivative or an antigen-binding fragment thereof as a single agent therapy for the prevention, treatment, management, or amelioration of cancer, particularly a T-cell malignancy, or one or more symptoms thereof. The present invention also encompasses the use of a CD2 antagonist, preferably MEDI-507, an analog, derivative or an antigen-binding fragment thereof in combination with other cancer therapies. The present invention provides pharmaceutical compositions comprising a CD2 antagonist, preferably MEDI-507, an analog, derivative or an antigen-binding fragment thereof in amounts effective to prevent, treat, manage, or ameliorate cancer, particularly a T-cell malignancy, or one or more symptoms thereof

The invention relates to the identification and selection of novel biomarkers and the identification and selection of novel biomarker combinations which are differentially expressed in osteoarthritis and / or in a particular stage of osteoarthritis, as well as a means of selecting the novel biomarker combinations. The biomarkers of the invention may be utilized to diagnose arthritis, differentiate between two stages of osteoarthritis and diagnose a particular stage of osteoarthritis. The invention provides kits comprising polynucleotides and / or proteins which specifically and / or selectively hybridize to the products of the biomarkers of the invention. Such kits are useful in diagnosing arthritis, differentiating between two stages of osteoarthritis, diagnosing a particular stage of osteoarthritis monitoring disease progression, and monitoring the efficacy of therapeutic regimens. The invention also provides for methods of using the products of the biomarkers of the invention in the identification of novel therapeutic targets for osteoarthritis.

A retractable needle assembly includes a housing having a sidewall defining a hollow bore, and an elongate plunger, the distal end of the plunger forming a reservoir within the hollow bore for containing a fluid therein. The plunger is adapted for slideable movement within the hollow bore. The assembly includes a hub disposed within the hollow bore and at least partially supporting a cannula therewith, and a needle retraction member engaged with the hub for manually selectable advancement with respect to a portion of the housing. The needle retraction member may be advanced from an initial position in which at least a portion of the needle is disposed outside the housing, to a retracted position in which the needle is fully surrounded by the housing. The elongate plunger may be advanced about the hub for extracting the fluid into the reservoir or expelling the fluid from the reservoir.

The present invention provides methods for stabilizing, reducing or eliminating cancer cells. In particular, the present invention provides prophylactically and / or therapeutically effective regimens for the prevention, treatment and / or management of cancer, the regimens comprising administering one or more cancer therapies to a subject to reduce a cancer cell population. The therapy(ies) in the prophylactically and / or therapeutically effective regimen can be administered at a lower dose than currently used or known to one of skill in the art and / or for a longer period of time and / or more frequently than currently administered or known to one of skill in the art.

A vehicle brake system includes a brake pedal unit coupled to a vehicle brake pedal. The system includes an input piston connected to operate a pedal simulator during a normal braking mode, and coupled to actuate a pair of output pistons during a manual push through mode. The output pistons are operable to generate brake actuating pressure at first and second outputs of the brake pedal unit. A hydraulic pressure source supplies fluid at a controlled boost pressure. A hydraulic control unit is adapted to be hydraulically connected to the brake pedal unit and the hydraulic pressure source. The hydraulic control unit includes a slip control valve arrangement, and a switching base brake valve arrangement for switching the brake system between the normal braking mode wherein boost pressure from the pressure source is supplied to first and second vehicle brakes, and the manual push through mode wherein brake actuating pressure from the brake pedal unit is supplied to the first and second vehicle brakes. The input piston cooperates with a seal mounted in the brake pedal unit to provide for a progressive rate of friction therebetween as the input piston is advanced in the brake pedal unit by the brake pedal.

The present invention relates to methods of reengineering or reshaping antibodies to reduce the immunogenicity of the antibodies, while maintaining the immunospecificity of the antibodies for an antigen. In particular, the present invention provides methods of producing antibodies immunospecific for an antigen by synthesizing a combinatorial library comprising complementarity determining regions (CDRs) from a donor antibody fused in frame to framework regions from a sub-bank of framework regions. The invention also provides method of producing improved humanized antibodies. The present invention also provides antibodies produced by the methods of the invention.

The present invention provides compositions, including pharmaceutical compositions, comprising an amount of an antibody, antibody fragment or antibody conjugate sufficient to treat Group A streptococcus (GAS) infection or complication thereof in a subject or a disease or complication associated with GAS infection in a subject wherein said antibody, antibody fragment or antibody conjugate binds immunospecifically to a B-cell epitope of GAS M-protein. The present invention also provides methods for the prophylactic or therapeutic treatment of infection by GAS and complications thereof comprising administering the compositions to a subject in need thereof.

The present invention relates to a method for screening and identifying compounds that modulate the activity tRNA splicing endonuclease. In particular, the invention provides assays for the identification of compounds that inhibit animalia tRNA splicing endonuclease. The methods of the present invention provide a simple, sensitive assay for high-throughput screening of libraries of compounds to identify pharmaceutical leads useful for treating and / or preventing cancer.

The present invention relates to a method for screening and identifying compounds that modulate the activity of one or more components in the tRNA splicing pathway. In particular the invention relates to a method for screening and identifying compounds that modulate the activity tRNA splicing endonuclease and / or tRNA splicing ligase. The invention provides assays for the identification of compounds that inhibit animalia tRNA splicing endonuclease and / or animalia tRNA splicing ligase. The invention also provides assays for the identification of compounds that inhibit fungal tRNA splicing endonuclease and / or fungal tRNA splicing ligase. The methods of the present invention provide a simple, sensitive assay for high-throughput screening of libraries of compounds to identify pharmaceutical leads useful for treating and / or preventing cancer and / or fungal infections.

The invention relates to the identification and selection of novel biomarkers and the identification and selection of novel biomarker combinations which are differentially expressed in individuals with bladder cancer as compared with individuals without bladder cancer. Polynucleotides and proteins which specifically and / or selectively hybridize to the products of the biomarkers of the invention are also encompassed within the scope of the invention as are kits containing said polynucleotides and proteins for use in diagnosing bladder cancer. Further encompassed by the invention is the use of the polynucleotides and proteins which specifically and / or selectively hybridize to the product of the biomarkers of the invention to monitor disease regression in an individual and to monitor the efficacy of therapeutic regimens. The invention also provides for methods of using the products of the biomarkers of the invention in the identification of novel therapeutic targets for bladder cancer.

The present invention provides methods of re-engineering or re-shaping an antibody from a first species, wherein the re-engineered or re-shaped antibody does not elicit undesired immune response in a second species, and the re-engineered or re-shaped antibody retains substantially the same antigen binding-ability of the antibody from the first species. In accordance with the present invention, a combinatorial library comprising the CDRs of the antibody from the first species fused in frame with framework regions derived from a second species can be constructed and screened for the desired modified antibody. In particular, the present invention provides methods utilizing low homology acceptor antibody frameworks for efficiently humanizing an antibody or a fragment thereof. The present invention also provides antibodies produced by the methods of the invention.